Hemolysis testing is an essential part of the biological evaluation of blood-contacting medical devices, as mandated by ISO 10993-4, ASTM F756, and GB/T 16886.4. This article provides a systematic analysis of the material, design, manufacturing, and testing variables that influence hemolytic outcomes, together with practical guidance on test methods, sample preparation, and regulatory expectations. Understanding these factors enables manufacturers to control hemolysis risk, optimize device design, and accelerate market approval worldwide.
Technical Overview
Hemolysis refers to the rupture of red blood cells (erythrocytes) and the subsequent release of hemoglobin into plasma. For medical devices that contact circulating blood, hemolysis is a primary indicator of blood compatibility and a mandatory consideration under ISO 10993-4, which identifies hemolytic effects as one of five key categories of blood-device interaction, alongside thrombosis, coagulation, platelet function, and complement activation. Clinically, excessive device-induced hemolysis can cause hemoglobinemia, anemia, renal tubular injury, and increased thrombotic risk, making it a critical safety endpoint.
The hemolytic potential of a device is quantified as the hemolysis ratio (hemolysis index), calculated by comparing free hemoglobin released from test samples against positive and negative controls. Under ASTM F756 and the guidance associated with GB/T 16886.4, a hemolysis ratio of 5% or less is generally considered acceptable, while results above this threshold typically require design modification, material substitution, or a documented scientific justification. Because hemolysis results are highly sensitive to experimental and design variables, a rigorous analysis of influencing factors is essential for producing reproducible, regulatorily defensible data.
Key Influencing Factors
Material-Related Factors
The chemical composition and surface chemistry of blood-contacting materials are dominant drivers of hemolysis. Specific contributors include:
- Residual monomers, oligomers, catalysts, and crosslinking agents that leach from polymeric materials such as PVC, polyurethane, and silicone.
- Plasticizers, antioxidants, stabilizers, colorants, and adhesive residues that migrate into blood.
- Metal ions released from stainless steel, cobalt-chromium, nickel-titanium, or titanium alloys, which can oxidize erythrocyte membranes.
- Surface roughness, wettability, and surface energy, which affect cell adhesion and membrane deformation.
- Degradation products from bioresorbable polymers or corrosion processes.
- Surface modifications and coatings, such as heparinization or hydrophilic coatings, which may either reduce or inadvertently increase hemolytic activity depending on formulation and durability.
Device Design and Hemodynamic Factors
Mechanical trauma from fluid shear stress is one of the most common causes of device-induced hemolysis. Erythrocytes tolerate only limited shear magnitude and exposure time, so design features that create high or turbulent shear are of particular concern:
- Narrow lumens, tight clearances, and abrupt changes in flow geometry that elevate local velocity gradients.
- Sharp edges, burrs, jet-forming orifices, and unpolished transitions that subject cells to instantaneous stress.
- Turbulent and recirculation zones downstream of connectors, Y-sites, and pump heads.
- High surface-area-to-blood-volume ratios, as in oxygenators, hemofilters, and long extracorporeal circuits.
- Roller pump occlusion settings and cavitation risk in blood pumps and ventricular assist systems.
- Extended blood contact duration, which compounds both chemical and mechanical effects.
Manufacturing, Processing, and Sterilization Factors
Post-processing conditions can substantially alter hemolytic behavior even when the base material is compliant:
- Machining marks, molding defects, weld seams, and residual burrs that act as localized shear sources.
- Cleaning residues such as detergents, surfactants, and organic solvents that remain on surfaces after inadequate rinsing.
- Residual ethylene oxide from gas sterilization, which is directly membrane-toxic.
- Radiation sterilization, which can induce oxidative degradation or alter polymer surface chemistry.
- Aging effects from storage, packaging interactions, and real-time or accelerated shelf-life exposure.
Blood-Related and In Vitro Test Condition Factors
Hemolysis assays are biologically variable, and several test parameters must be tightly controlled to avoid false positives or negatives:
- Blood species and donor variability; fresh rabbit or human blood is commonly specified, and blood must be tested within a defined post-draw window.
- Anticoagulant selection, typically heparin or sodium citrate, and its concentration.
- Hematocrit of the diluted blood suspension, which influences the concentration of released hemoglobin.
- Incubation temperature and time, typically 37 °C for two to three hours or per the chosen protocol.
- Extraction ratio (surface area to extraction vehicle volume), extraction medium, and extraction conditions when following ISO 10993-12.
- Centrifugation speed and duration, which affect residual intact cells in the supernatant.
- Spectrophotometric measurement conditions, with absorbance commonly read at 540 nm to 545 nm.
- Handling artifacts such as vigorous mixing, air bubbles, or excessive pipetting shear.
Testing Samples
Externally Communicating Devices
Devices that interface with the blood path outside the body are the most frequently tested category, including intravenous and central venous catheters, infusion sets, hemodialysis circuits and dialyzers, extracorporeal membrane oxygenation (ECMO) components, blood oxygenators, cardiotomy reservoirs, apheresis tubing sets, and blood transfer and collection devices.
Implant Devices
Long-term blood-contacting implants require rigorous hemolysis evaluation, including coronary and peripheral stents, heart valve prostheses, vascular grafts and stent-grafts, septal occluders, ventricular assist devices, and implantable pumps.
Raw Materials and Components
Material-level screening is performed early in development using polymer coupons, metal samples, tubing segments, films, coatings, adhesives, and elastomer specimens to compare candidate materials before device-level integration.
Testing Items
Core hemolysis evaluations typically include the following parameters:
- Hemolysis ratio (hemolysis index) determined by the direct contact method.
- Hemolysis ratio determined by the indirect extraction method.
- Free hemoglobin or plasma hemoglobin concentration in the supernatant.
- Supporting ISO 10993-4 blood-interaction endpoints where required, such as partial thromboplastin time, thrombin generation, platelet count and morphology, complement activation markers (C3a, SC5b-9), and leukocyte counts.
- Ancillary characterizations that assist root-cause analysis, including extractables and leachables profiling, surface roughness measurement, and contact angle analysis.
Testing Methods
Direct Contact Method
In the direct contact method, the test sample is placed in direct contact with diluted, anticoagulated whole blood and incubated at 37 °C, typically for two to three hours with gentle inversion at defined intervals. After incubation, the blood is centrifuged and the absorbance of the supernatant is measured spectrophotometrically at approximately 540 nm. This method captures both surface-mediated and mechanically induced hemolysis and is well suited to catheter segments, films, and sectioned device components.
Indirect Extraction Method
In the extraction method, the sample is first extracted in saline or phosphate-buffered saline under conditions defined by ISO 10993-12, commonly 37 °C for 24 hours at a standard surface-area-to-volume ratio. The resulting extract is then incubated with diluted blood. This approach isolates hemolysis caused by leachable chemical species and is appropriate for devices that cannot be conveniently sectioned, materials with high extractable content, or regulatory protocols that emphasize chemical compatibility.
Controls, Calculation, and Acceptance Criteria
Each assay includes a positive control, typically distilled water or a saponin solution, which produces complete hemolysis, and a negative control, typically phosphate-buffered saline, which produces negligible hemolysis. The hemolysis ratio is calculated as the difference between the sample absorbance and the negative control absorbance, divided by the difference between the positive and negative control absorbances, multiplied by 100%. A hemolysis ratio of 5% or below is generally regarded as non-hemolytic. Control results must fall within validated ranges for the test to be considered valid.
Quality Measures to Reduce Variability
To ensure reproducibility, testing should be performed in accordance with good laboratory practice in qualified facilities or accredited third-party laboratories, using fresh blood from consistent sources, calibrated spectrophotometers, validated centrifugation parameters, an adequate number of replicate samples, and standardized written procedures. Any deviation should be documented and justified in the final report.
Applications
Hemolysis influencing-factor analysis and testing support a wide range of regulatory and engineering activities:
- Regulatory submissions, including national market authorization dossiers, premarket notifications, and CE technical documentation under the EU MDR.
- Design verification and optimization of blood-contacting geometries to minimize shear-induced cell damage.
- Material selection and comparative screening during early-stage research and development.
- Risk management documentation aligned with ISO 14971, linking hemolysis hazards to mitigation measures.
- Change control evaluation following material substitution, supplier changes, process modifications, or sterilization changes.
- Root-cause investigation of adverse hemolysis findings through combined biological and physicochemical testing.
FAQ
What hemolysis ratio is considered acceptable?
A hemolysis ratio of 5% or less is widely accepted as non-hemolytic under ASTM F756 and the guidance associated with GB/T 16886.4. Some evaluation schemes apply stricter internal limits, particularly for long-duration or high-flow implants such as ventricular assist devices.
Which standards govern hemolysis testing?
ISO 10993-4 defines the overall framework for blood-interaction testing, ASTM F756 details hemolytic analysis of materials, and GB/T 16886.4 provides the corresponding requirements in the Chinese regulatory system. ISO 10993-12 governs sample preparation and extraction conditions.
Should rabbit or human blood be used?
Both fresh rabbit blood and fresh human blood are accepted by common protocols. Rabbit blood is frequently used due to availability and consistency, while human blood may better reflect clinical exposure. Blood must be freshly drawn and tested within the time window specified in the validated protocol.
When should the direct contact method versus the extraction method be used?
The direct contact method is preferred when physical surface interaction and mechanical effects are of concern, such as with tubing, catheters, and circuit components. The extraction method is preferred when leachable chemicals are the primary concern or when the device geometry prevents meaningful direct contact. Many programs perform both to fully characterize risk.
What should be done if a sample exceeds the 5% threshold?
An exceedance should trigger a structured investigation: review test artifacts such as shear during handling, evaluate the contribution of design geometry and flow-induced stress, screen extractables for hemolytic substances, and verify cleanliness and sterilant residues. Mitigation options include surface finishing improvements, material substitution, coating application, or design changes to reduce shear zones, followed by confirmatory retesting.
How does sterilization influence hemolysis results?
Sterilization can alter hemolytic behavior through residual ethylene oxide toxicity, radiation-induced polymer oxidation, or changes in surface chemistry. Sterilized, final-configured samples should be tested whenever possible, and sterilization residuals must be within established limits before biological evaluation.